^
    Back
    Association details:
    Biomarker:NRG1 fusion
    Cancer:Pancreatic Cancer
    Drug:zenocutuzumab (MCLA-128) (HER2 inhibitor, HER3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

    Excerpt:
    ...- Patient with advanced metastatic solid tumor with documented NRG1 fusion determined in a qualified local laboratory by molecular profiling using methods such as next generation sequencing [DNA or RNA] or FISH as routinely performed at CLIA or other similarly-certified laboratories....
    Trial ID:
    NCT04100694
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

    Excerpt:
    ...Evaluation of clinical benefit assessed by RECIST v1.1 determining objective overall response rate (ORR)`To assess durability of anti-tumor activity of MCLA-128 in patients with NRG1 fusions as assessed locally...
    Trial ID:
    NCT02912949
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.

    Published date:
    05/19/2021
    Excerpt:
    Zeno induces rapid and major radiologic tumor regression and biomarker responses in heavily-pretreated metastatic KRAS wild-type NRG1+ pancreas cancer, with minimal toxicity.
    DOI:
    10.1200/JCO.2021.39.15_suppl.3003
    Trial ID:
    NCT02912949